August 1, 2017 | Silenseed, an Israeli, clinical-stage bio-pharmaceutical company that develops cancer therapies, is raising $10 million. Founded in 1999 by Amotz Shemi, the company is planning to use the money to fund the second phase of a trial, which was recently approved by the FDA, to develop a pancreatic cancer treatment. Silenseed uses a targeted RNA interference (RNAi) to develop the cancer drugs and delivery systems for treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments